EAN 2021 | BTK inhibitors gain ground in MS
Nikolaos Grigoriadis
• 8 Jun 2021
Nikolaos Grigoriadis, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, explains that Bruton’s tyrosine kinase (BTK) inhibitors hold great promise as treatments for multiple sclerosis (MS), with several ongoing trials. Although evidence for the efficacy of BTK inhibitors from molecular studies, animal models, and basic science appears promising, Dr Grigoriadis suggests a cautious approach due to the unpredictable nature of MS. This interview took place during the European Academy of Neurology 2021 congress.
